Evidence map›Paper›PMID 15795375›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2005

23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A-->G.

Peter Pfister, Natascia Corti, Sven Hobbie, Christian Bruell, Raz Zarivach, Ada Yonath, Erik C Böttger

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 80 citations in OpenAlex.

  1. Trial
  2. Article
  3. Resurgence ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
  4. Article
  5. Expanding the Scope of Protein Synthesis Using Modified Ribosomes.Journal of the American Chemical Society · 2019
    Article
  6. Article
  7. The macrolide antibiotic renaissance.British journal of pharmacology · 2017
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The structure of ribosome-lankacidin complex reveals ribosomal sites for synergistic antibiotics.Proceedings of the National Academy of Sciences of the United States of America · 2010
    Article
  15. Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity.Proceedings of the National Academy of Sciences of the United States of America · 2008
    Article
  16. Macrolide myths.Current opinion in microbiology · 2008
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Peter PfisterInstitut für Medizinische Mikrobiologie, Universität Zürich, Gloriastrasse 30/32, CH-8006 Zürich, Switzerland.
Natascia Corti
Sven Hobbie
Christian Bruell
Raz Zarivach
Ada Yonath
Erik C Böttger
University of Zurich · CHWeizmann Institute of Science · IL

Funding

CRYSTALLOGRAPHIC STUDIES ON RIBOSOMAL PARTICLESR01GM034360 · NIGMS · WEIZMANN INSTITUTE OF SCIENCE · PI YONATH, ADA E · 1985 to 2010
$2.2M
NIGMS NIH HHS GM34360NIGMS NIH HHS R01 GM034360
6 · The paper itself

Abstract

The 23S rRNA A2058G alteration mediates macrolide, lincosamide, and streptogramin B resistance in the bacterial domain and determines the selectivity of macrolide antibiotics for eubacterial ribosomes, as opposed to eukaryotic ribosomes. However, this mutation is associated with a disparate resistance phenotype: It confers high-level resistance to ketolides in mycobacteria but only marginally affects ketolide susceptibility in streptococci. We used site-directed mutagenesis of nucleotides within domain V of 23S rRNA to study the molecular basis for this disparity. We show that mutational alteration of the polymorphic 2057-2611 base pair from A-U to G-C in isogenic mutants of Mycobacterium smegmatis significantly affects susceptibility to ketolides but does not influence susceptibility to other macrolide antibiotics. In addition, we provide evidence that the 2057-2611 polymorphism determines the fitness cost of the 23S rRNA A2058G resistance mutation. Supported by structural analysis, our results indicate that polymorphic nucleotides mediate the disparate phenotype of genotypically identical resistance mutations and provide an explanation for the large species differences in the epidemiology of defined drug resistance mutations.

Indexed as

Point MutationBase SequenceBinding SitesClarithromycinDrug Resistance, BacterialKetolidesMacrolidesModels, MolecularMolecular Sequence DataMutagenesis, Site-DirectedMycobacterium smegmatisNucleic Acid ConformationPhenotypeRNA, BacterialRNA, Ribosomal, 23SSpecies SpecificityClarithromycinKetolidesMacrolidesRNA, BacterialRNA, Ribosomal, 23StelithromycinTylosin

Identifiers

PMID15795375
PMCPMC555689
OpenAlexW2053754431

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.